Myqorzo (aficamten) is a new therapy for oHCM, improving functional capacity and symptoms, with an annual cost of $108,400. The Myqorzo & You program provides personalized support, including insurance ...
Gemtesa’s manufacturer (Urovant Sciences) provides the Gemtesa Simple Savings Program. This is a financial assistance plan aimed at making Gemtesa (vibegron) — a treatment for overactive bladder in ...
ROCHESTER, N.Y. – Those who care for loved ones on Medicaid were promised health insurance but getting that coverage has been an uphill battle. Lisa Robinson is a full-time caregiver for her adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results